William J. Irvin Jr., MD

Overview

Gender

Male

Languages

English

Specialties

Oncology and Hematology

Cancer Care

Biography

Dr. Irvin is the Medical Director of Medical Oncology, Virginia and the Director of Clinical Research for the Bon Secours Cancer Institute.  He joined Bon Secours Cancer Institute from faculty at the University of North Carolina (UNC) where he developed a specialty in breast cancer.  At UNC, he led a nationally recognized clinical trial on pharmacogenetic dosing of tamoxifen. His research interests include overcoming endocrine resistance in breast cancer, triple negative breast cancer, and breast cancer in young women. He attended the University of Virginia for his undergraduate degree and received his medical degree from Virginia Commonwealth University School of Medicine.  He completed his Internal Medicine residency from Virginia Commonwealth University.  From there, Dr. Irvin completed a Hematology and Oncology fellowship at the University of North Carolina.  Dr. Irvin is board certified by the American Board of Internal Medicine in Medical Oncology and Hematology.  He serves on the Breast Committee and the Translational Breast Committee of the NRG, and on the governing and executive councils for the Southeast Clinical Oncology Research Consortium (SCOR).  Dr. Irvin is originally from Richmond and is thankful for the love and support of his wife and his three children. 

recent publications

Books and chapters:

Irvin W, Muss H. Clinical Trials in the Elderly. In: Naeim, Reubin, and Ganz eds. Management of Cancer in the Older Patient. Philadelphia, PA: Elsevier Saunders, 2012, p. 103-108.

Irvin W, Amos K. Chapter 83: Selection of patients for therapy. In: Kuerer, ed. Kuerer’s Breast Surgical Oncology. New York, NY: McGraw-Hill Professional, 2010, p.867-875.

Irvin W, Carey LA. Breast Cancer. In: Kilzer N, ed. World Book Encyclopedia. (Electronic Product). Chicago, IL: World Book Publishing; 2008, 591.

Refereed papers/articles:

Original research:

Paoletti C, Li Y, Muñiz MC, Kidwell KM, Aung K, Thomas DG, Brown ME, Abramson VG, Irvin WJ Jr., Lin NU, Liu MC, Nanda R, Nangia JR, Storniolo AM, Traina TA, Vaklavas C, Van Poznak CH, Wolff AC, Forero-Torres A, Hayes DF; Translational Breast Cancer Research Consortium (TBCRC). Significance of Circulating Tumor Cells in metastatic triple negative breast cancer patients within a randomized, phase II trial TBCRC 019. Clin Cancer Res. 2015 Jun 15; 21 (12): 2771-9. Epub 2015 Mar 16. PMID 25779948.

Hertz DL, Snavely AC, McLeod HL, Walko CM, Ibrahim JG, Anderson S, Weck KE, Magrinat G, Olajide O, Moore S, Raad R, Carrizosa DR, Corso S, Schwartz G, Pepperson JM, Evans JP, Jones DR, Desta Z, Flockhart DA, Carey LA, Irvin WJ Jr. Br J Clin Pharmacol. 2015 Apr 24. Epub ahead of print. PMID 25907378.

Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ Jr., Krontiras H, De Los Santos JF, Haluska P, Grizzle W, Meyers RM, Wolff AC; Translational Breast Cancer Research Consortium (TBCRC). TBCRC 019: An phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with metastatic triple negative breast cancer. Clin Cancer Res. 2015 Jun 15; 21 (12): 2722-9; Epub 2015 Mar 16. PMID 25779953.

Hertz DL, Deal A, Ibrahim JG, Walko CM, Weck KE, Anderson S, Magrinat, G, Olajide O, Moore S, Raab R, Carrizosa D, Corso S, Schwartz G, Graham M, Peppercorn JR, Jones DR, Desta Z, Flockhart DA, Evans JP, McLeod HL, Carey LA, Irvin Jr W. Tamoxifen Dose Escalation in Patients with Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations without Increasing Toxicity. Oncologist. 2016 May 25. Epub ahead of print. PMID: 27226358.

Hertz DL, Snavely AC, McLeod HL, Walko CM, Ibrahim JG, Anderson S, Weck KE, Magrinat G, Olajide O, Moore S, Raad R, Carrizosa DR, Corso S, Schwartz G, Pepperson JM, Evans JP, Jones DR, Desta Z, Flockhart DA, Carey LA, Irvin WJ Jr. In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles. Br J Clin Pharmacol. 2015 Apr 24. Epub ahead of print. PMID 25907378.

Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ Jr., Krontiras H, De Los
Santos JF, Haluska P, Grizzle W, Meyers RM, Wolff AC; Translational Breast Cancer Research Consortium (TBCRC). TBCRC 019: A phase II trial of nanoparticle albumin-bound paclitaxel with
or without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with metastatic triple negative breast cancer. Clin Cancer Res. 2015 Jun 15; 21 (12): 2722-9; Epub 2015 Mar 16. PMID 25779953.

Paoletti C, Li Y, Muñiz MC, Kidwell KM, Aung K, Thomas DG, Brown ME, Abramson VG, Irvin WJ Jr., Lin NU, Liu MC, Nanda R, Nangia JR, Storniolo AM, Traina TA, Vaklavas C, Van Poznak CH, Wolff AC, Forero-Torres A, Hayes DF; Translational Breast Cancer Research Consortium (TBCRC). Significance of Circulating Tumor Cells in metastatic triple negative breast cancer patients within a randomized, phase II trial TBCRC 019. Clin Cancer Res. 2015 Jun 15; 21 (12): 2771-9. Epub 2015 Mar 16. PMID 25779948.

Brewer NT, DeFrank JT, Chiu WK, Ibrahim JG, Walko CM, Rubin P, Olajide OA, Moore SG, Raab RE, Carrizosa DR, Corso SW, Schwartz G, Peppercorn JM, McLeod HL, Carey LA, and Irvin Jr WJ.
Patients’ understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer. Public Health Genomics. Jan 2014; (21): 43-47. PMID: 24457521. Hertz DL, McLeod HL, Irvin WJ Jr. Tamoxifen and CYP2D6: A contradiction of data. Oncologist. 2012 Apr 24. Epub ahead of print. PMID: 22531359.

He YJ, Misher AD, Irvin WJ, Motsinger-Reif A, McLeod HL, Hoskins, JM. Assessing the utility of whole genome amplified DNA as a template for DMET Plus microarray. Clin Chem Lab Med. 2012 Feb 14; 50 (8): 1329-34. PMID: 22868796.

Irvin W Jr, Muss HB, Mayer DK. Symptom Management in Metastatic Breast Cancer. Oncologist. 2011; 16(9); 1203-14. Epub 2011 Aug 31. PMID: 21880861.

Irvin WJ Jr, Walko CM, Weck KE, Ibrahim JG, Chiu WK, Dees, EC, Moore SG, Oludamilola OA, Graham ML, Canale ST, Raab RE, Corso SW, Peppercorn JM, Anderson SM, Friedman KJ,Ogburn
ET, Desta Z, Flockhart DA, McLeod HL, Evans JP, Carey LA. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: A multicenter study. J Clin Oncol 29. 2011 Aug 20; 29(24): 3232-9. Epub 2011 Jul 18. PMID 21768473.